http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Bin Li,Sang-Bin Lee,Kozo Watanabe,Dong-HwanKim,Muyoung Heo,Young-Seuk Park,Tae-Soo Chon 한국응용곤충학회 2016 한국응용곤충학회 학술대회논문집 Vol.2016 No.04
Investigating loci compositions by conventional methods is limited in fully addressing complex gene information. We applied self-organizing map (SOM) to characterize Amplified Fragment Length Polymorphism (AFLP) of aquatic insects in six streams in Japan in responding to environmental variables. Locus band presence patterns were clustered by the trained SOM. Presence and absence data of loci were altered and cluster change through recognition was Subsequently expressed to indicate sensitivity to environmental variables. The outlier loci were determined based on the 90th percentile. Subsequently environmental responsiveness was obtained for each outlier in different species. Outlier loci were overall sensitive to pollutants and feeding material. Poly-loci like responsiveness was detected in adapting to environmental constraints. SOM training combined with recognition could be an efficient means of characterizing loci information without knowledge on population genetics a prior.
( Yun Bin Lee ),( Yeonjung Ha ),( Young Eun Chon ),( Mi Na Kim ),( Joo Ho Lee ),( Hana Park ),( Kyu Sung Rim ),( Seong Gyu Hwang ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: As nonalcoholic fatty liver disease becomes a worldwide epidemic, hepatic steatosis has been frequently demonstrated in chronic hepatitis B patients without excessive alcohol intake. Whether presence of hepatic steatosis in these patients is associated with higher risk of developing hepatocellular carcinoma (HCC) has not been well established. We investigated the impact of histologically proven hepatic steatosis on the risk of HCC development. Methods: Chronically hepatitis B virus-infected patients without significant alcohol consumption, who underwent liver biopsy from January 2007 to December 2015 in a single centre, were consecutively included. Patients were categorised into two groups according to the presence or absence of hepatic steatosis ≥ 5%, and the association of steatosis with subsequent HCC risk was analysed. To adjust for differences in patient characteristics including metabolic features, inverse probability weighting (IPW) using propensity scores was used. Results: Hepatic steatosis was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9-8.3) years, 17 of 321 patients (5.3%) developed HCC: 9 of 251 patients (3.6%) without steatosis and 8 of 70 patients (11.4%) with steatosis. The 5-year cumulative incidences of HCC were 1.9% and 8.2% among patients without steatosis and with steatosis, respectively (P=.004) (Figure A). Steatosis was associated with higher risk of HCC development (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122-8.051; P=.029). After balancing with IPW, the incidences of HCC were not significantly different between the groups (P=.187) (Figure B), and the association between steatosis and HCC development was not significant (adjusted HR, 2.292; 95% CI, 0.693-7.587; P=.17). Conclusions: Hepatic steatosis was associated with higher risk of developing HCC in patients with chronic hepatitis B. However, the association of steatosis per se with HCC development was not evident after adjustment for metabolic characteristics.
( Young Eun Chon ),( Seong Gyu Hwang ),( Kyu Sung Rim ),( Mi Na Kim ),( Hana Park ),( Yun Bin Lee ),( Joo Ho Lee ),( Yeonjung Ha ),( Mi Jung Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Although non-alcoholic fatty liver disease (NAFLD) is associated with increased risk of incident chronic kidney disease (CKD) development, association between the severity of NAFLD and CKD incidence has not been elucidated. This study investigated the association between the fibrosis in NAFLD and development of incident CKD in a large cohort study. Methods: Among 10,030 subjects in Ansan and Ansung community based cohort in Korea, 6,854 subjects were finally analyzed after excluding patients with excessive alcoholic consumption or CKD at baseline. NAFLD was defined by NAFLD liver fat score, fatty liver index, or hepatic steatosis index. Degree of liver fibrosis was assessed by NAFLD fibrosis score. Incident CKD was defined as eGFR <60 ml/min per 1.73 m<sup>2</sup> at any time. Results: During 12-years of follow-up period, CKD developed in 1344 subjects (19.6%). NAFLD was a significant predictor for development of incident CKD after adjusting other confounders (using NAFLD liver fat score; odds ratio [OR], 1.24; 95% confidence interval [CI], 1.09- 1.42). In subjects with NAFLD (n=1807, using NAFLD liver fat score), multivariate logistic regression analysis demonstrated an independent association between advanced liver fibrosis assessed by NAFLD fibrosis score and incident CKD development (OR, 1.23; 95% CI, 1.02-1.49). Conclusions: Presence of NAFLD and the amount of fibrosis in NAFLD were independently associated with incident CKD development, and the associations were independent of metabolic syndrome.
내독소를 투여한 백서의 패혈증 모델에서 glutamine 및 N-Acetylcysteine 투여가 간내 항산화에 미치는 효과
천성빈 ( Song Bin Chon ),김지수 ( Jee Soo Kim ),이창현 ( Chang Hyun Lee ),정성은 ( Sung Eun Jung ),윤여규 ( Yeo Kyu Youn ),서길준 ( Gil Joon Suh ) 대한외상학회 2004 大韓外傷學會誌 Vol.17 No.1
Background: Glutathione (GSH) has been known to be an important intracellular antioxidant. The aim of this study was to investigate the effects of the glutamine and N-acetylcysteine (NAC) on lipid peroxidation and antioxidant effect in sepsis model. Methods: All female Sprague-Dawley rats were given an intraperitoneal diethylmaleate (DEM) injection before treatment, and divided into four groups: control group (DEM only), lipopolysaccharide (LPS) treated group (DLPS), LPS with glutamine treated group (DLPG) and LPS with both glutamine and NAC treated group (DLPGC). Animals were killed at 6 and 24 hours after treatment. The histology and the counts of the infiltrative neutrophils, and the levels of malondialdehyde (MDA) and GSH in the liver were measured. Results: While the liver histology in the both DLPG and DLPGC groups showed mild neutrophil infiltration, vacuolization of hepatocytes, and the sinusoidal dilation compared to those of the DLPS group, there was no significant change of the neutrophil counts between the treatment groups. Both the DLPG and DLPGC groups showed decreases in liver MDA level compared to the DLPS group. Although both the DLPG and DLPGC groups demonstrated significant increases in the liver GSH level compared to the DLPS group, there was no significant change between the DLPG and DLPGC groups. Conclusion: This study showed that the administration of the glutamine and NAC in sepsis model revealed an inhibition of the lipid peroxidation and an antioxidant effect through the increase of GSH in the liver.
( Young Eun Chon ),( Kyu Sik Jung ),( Seong Gyu Hwang ),( Kyu Sung Rim ),( Mi Na Kim ),( Hana Park ),( Yun Bin Lee ),( Joo Ho Lee ),( Yeonjung Ha ),( Sang Hoon Ahn ),( Do Young Kim ),( Kwang-hyub Han 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Long term suppression of hepatitis B virus with tenofovir (TDF) is known to induce fibrosis regression, and repeated liver stiffness (LS) measurement can indicate the regression of fibrosis. We aimed to investigate predictors for fibrosis improvement assessed by LS changes in patients receiving long-term TDF therapy in chronic hepatitis B (CHB) with liver cirrhosis. Methods: CHB patients with histologically proven liver cirrhosis who received TDF as the first-line therapy from 2011 to 2016 were recruited. LS and controlled attenuation parameter (CAP) measurements were repeated at baseline and 3 years after therapy. Fibrosis improvement was defined as a drop of LS value ≥30% from the baseline. Results: A total of 119 patients were enrolled (mean age 21.3 and male 67.2%). After 3 years of TDF therapy, the mean LS value has significantly improved (from 14.7 kPa to 8.7 kPa, P<0.001), and 85 (71.4%) patients have achieved fibrosis improvement. Predictors associated with improvement of LS were low body mass index (BMI), HBeAg positivity, and low CAP value at baseline. In multivariate analysis, low BMI was a single factor independently associated with fibrosis regression (odds ratio 0.642, 95% CI 0.515-0.800, P<0.001). Patients with BMI<23.5, had a 2.1 times more chance of achieving fibrosis regression compared to those with BMI ≥23.5. (89.2% vs. 42.2%, P=0.001) Conclusions: High BMI was a single significant factor hindering the fibrosis improvement in patients receiving long-term TDF therapy in chronic hepatitis B with liver cirrhosis. Life style modification and BMI reduction should be encouraged to enhance fibrosis improvement.
( Yeonjung Ha ),( Young Eun Chon ),( Yun Bin Lee ),( Mi Na Kim ),( Joo Ho Lee ),( Hana Park ),( Seong Gyu Hwang ),( Kyu Sung Rim ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Previous studies have shown inconsistent results regarding the association between vitamin D insufficiency and nonalcoholic fatty liver disease. Methods: We attempted to demonstrate this relationship using population-based data. Data of the Sixth Korea National Health and Nutrition Examination Survey were reviewed. Vitamin D insufficiency was defined as a 25(OH)D level ≤20 ng/mL. Hepatic steatosis index was calculated to define NAFLD. Significant fibrosis was assessed using Body mass index, AST/ALT Ratio, Diabetes (BARD) score. Logistic regression analyses were performed to determine the relationship between vitamin D insufficiency and nonalcoholic fatty liver disease. Results: Among 1,812 participants, 409 (22.6%) had nonalcoholic fatty liver disease. Patients with nonalcoholic fatty liver disease were more likely to be male (56.7%), had higher body mass index (28.1 kg/m2), and had more metabolic syndrome (57.2%). The proportion of vitamin D insufficiency did not differ between nonalcoholic fatty liver disease and non- nonalcoholic fatty liver disease (77.5% vs. 77.4%). Logistic regression analyses showed that BMI, diabetes, and triglyceride level were significantly associated with nonalcoholic fatty liver disease, whereas vitamin D insufficiency was not related. Subgroup analyses involving nonobese participants, male participants, and participants without metabolic syndrome showed similar results. The BARD score and the proportion of significant fibrosis by BARD score did not differ according to vitamin D status. Conclusions: Vitamin D insufficiency was not associated with the presence of nonalcoholic fatty liver disease.
( Yeonjung Ha ),( Young Eun Chon ),( Yun Bin Lee ),( Mi Na Kim ),( Joo Ho Lee ),( Hana Park ),( Seong Gyu Hwang ),( Kyu Sung Rim ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Terlipressin is the most commonly used agent in patients with type 1 hepatorenal syndrome (HRS-1). The effect of early administration of terlipressin on short- and long-term survival was evaluated. Methods: Cirrhotic patients treated with terlipressin due to renal impairment (N = 60) between Jan 2006 and Jun 2016 were identified. The patients were divided into: 1) early administration (EA, n=23) and 2) conventional administration (CA, n=37) groups. EA consisted of patients who received terlipressin before HRS-1 diagnosis, whereas CA included patients treated with terlipressin after HRS-1 diagnosis. The 2-week and 3-month survival differences were evaluated. Factors associated with survival were assessed using Cox-proportional hazards model. Results: Creatinine levels (4.3 ± 2.7 vs. 2.0 ± 0.4; P <0.001) and Child-Pugh scores were higher in the CA group (11.2 ± 2.0 vs. 10.0 ± 1.9; P=0.038). The 2-week survival time was not significantly different between the two groups (78% for EA vs. 54% for CA; P=0.06). Baseline creatinine levels (hazards ratio [HR] = 1.17), Child-Pugh score (HR=1.45), and decrease in creatinine levels at day 3 (HR=0.29) were significantly associated with 2-week survival (all Ps <0.05). For 3-month, the EA group was not associated with higher survival (43.5% for EA vs. 34.0% for CA; P=0.33). Child-Pugh score (HR=1.39) and decrease in creatinine levels at day 3 (HR=0.30) predicted 3-month survival (all Ps <0.05). Conclusions: Although terlipressin is widely used in clinical practice, even in less severe kidney injury, the early administration of terlipressin did not exhibit any survival benefits.
( Yeonjung Ha ),( Young Eun Chon ),( Yun Bin Lee ),( Mi Na Kim ),( Joo Ho Lee ),( Hana Park ),( Seong Gyu Hwang ),( Kyu Sung Rim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: The prognostic impact of sarcopenia has not been clearly demonstrated in patients newly diagnosed with hepatocellular carcinoma (HCC), especially those without symptoms. Methods: Area of skeletal muscle and abdominal fat were measured at L3 level of computed tomography scan in 132 patients newly diagnosed with HCC between Jan 2007 to Jun 2011. Sarcopenia was defined as L3 skeletal muscle index of ≤ 52.4 cm/m2 for male and ≤ 38.5 cm/m2 for female. Baseline data were analyzed to determine the effect of sarcopenia on overall survival (OS) using the univariate and Cox multivariate analyses in overall and propensity- score matched cohorts. The impact of sarcopenia in asymptomatic vs. symptomatic patients was subsequently evaluated. Results: Sarcopenic patients (32 out of 132) were older (65.3 vs. 57.0 years old) and had lower body mass index (21.0 vs. 24.0 kg/m2), total fat (55.7 vs. 68.0 cm2/m2), and subcutaneous fat (21.9 vs. 29.2 cm2/m2) area. The presence of sarcopenia dichotomized patients with regard to OS (median 41.2 vs. 13.8 months, P=0.001). Multivariate analysis found that sarcopenia (hazard ratio [HR], 2.15, P=0.008), alpha-fetoprotein (HR, 2.79, P=0.004), Child-Pugh stage (HR, 2.38, P=0.017), infiltrative tumor (HR, 2.29, P=0.021), and BCLC stage (P<0.001) were predictive of OS. In a propensity score-matched cohort, sarcopenia (HR, 5.50, P=0.027) was the only predictive factor. In particular, asymptomatic patients with sarcopenia had a poor OS than patients without sarcopenia (median 69.6 vs. 22.2 months, P<0.001), while no significant difference in symptomatic patients (median 17.2 vs. 9.7 months, P=0.26). Subdividing asymptomatic patients of BCLC A and B stages according to sarcopenia status improved the predictive ability of staging system (c-index, 0.87 vs. 0.67, P<0.001). Conclusions: Sarcopenia is an independent prognostic factor in patients newly diagnosed with HCC, especially those without symptoms. Subdividing BCLC A and B stages according to sarcopenia status showed a better stratification.